Fields of Interest: Critical Care Medicine, Cardiovascular Physiology and Metabolism, Heart Failure, Mechanical Circulatory Assist Devices, Artifical Organs and Organ Replacement Therapy, Thoracic Organ Transplantation in all Age Groups, Immunology, Organ Pres

Michael M. Koerner was born in 1952 and graduated from the Univ of Duesseldorf in West Germany with a MD in 1981 and PhD in 1982. His residency and part of his fellowship were also done at the Heinrich Heine University of Duesseldorf. He finished his fellowship at the Ruhr-University of Bochum at the Heart Center Northrhine-Westphalia in Bad Oeynhausen.

Prior to joining the Baylor College of Medicine, he was at the Heart Center Northrhine-Westphalia for 15 years, where, together with the Surgery Department, he introduced and established the Mechanical Circulatory Support Program since 1987. He has extensive experience in internal intensive care with all types of mechanical assist devices both pulsatile and non-pulsatile for support of the left and right ventricles, or both with or with-out extracorporeal membrane oxygenation and continuous high volume veno-venous hemofiltration.

He designed and established the Heart Center‘s Thoracic Organ Transplant Program for pediatric and adult recipients in 1988, and was the Medical Director of the Heart Failure and Thoracic Organ Transplant Program until December 1999. This program is one of the most active and successful ones in the world, having performed 1030 thoracic organ transplants between March 1989 and December 1999, and over 500 patients supported with mechanical circulatory assist devices.

He established an individual immunosuppressive protocol for heart recipients consisting, when possible, of an induction of immunosuppression without any antibody therapy and after the first year, with an immunosuppressive maintenance with cyclosporine alone or without steroids. This protocol has an overall five-year survival rate of 75%. The five-year survival of children after cardiac transplantation and surveillance with-out endomyocardial biopsies is even 90%.

After being a visiting research Assistant Professor Faculty from 7/99 to 12/99 at the Baylor College of Medicine, he left the Heart Center Northrhine-Westphalia and joined the Faculty of Baylor College of Medicine in 1/00 as an Assistant Professor in the Section of Cardiology. Since then he is in the Baylor Heart Clinic, staff member of the Heart Failure and Cardiac Transplant Program, as well as the Methodist Hospital and the Winters Heart Failure Center for Research.

He also still holds a lectureship in Internal Medicine at the Ruhr-University of Bochum in West Germany.

His research has focused on circulatory, heart- and lung failure management with pharmacological, electrical and/or mechanical cardiopulmonary assist devices as alternatives or bridging to thoracic organ transplantation, management of the organ donor and recipient, and individual immunmodulation.

Lisman KA, Stetson SJ, Koerner MM, Farmer JA, Torre-Amione G
Managing heart failure with immunomodulatory agents.
Cardiol Clin. 2001 Nov;19(4):617-25.
Abstract

Stetson SJ, Perez-Verdia A, Mazur W, Farmer JA, Koerner MM, Weilbaecher DG, Entman ML, Quinones MA, Noon GP, Torre-Amione G
Cardiac hypertrophy after transplantation is associated with persistent expression of tumor necrosis factor-alpha.
Circulation. 2001 Aug 7;104(6):676-81.
Abstract

Koerner MM, Loebe M, Lisman KA, Stetson SJ, Lafuente JA, Noon GP, Torre-Amione G
New strategies for the management of acute decompensated heart failure.
Curr Opin Cardiol. 2001 May;16(3):164-73.
Abstract

Castella M, Tenderich G, Koerner MM, Arusoglu L, El-Banayosy A, Schulz U, Schulze B, Schulte-Eistrup S, Wolff C, Minami K, Koerfer R
Outcome of heart transplantation in patients previously infected with hepatitis C virus.
J Heart Lung Transplant. 2001 May;20(5):595-8.
Abstract

Perez-Verdia A, Stetson SJ, McRee S, Mazur W, Koerner MM, Torre-Amione G
The effect of cytokines on cardiac allograft function: tumor necrosis factor alpha a mediator of chronic injury.
Heart Fail Rev. 2001 Mar;6(2):137-41.


Bruckner BA, Stetson SJ, Perez-Verdia A, Youker KA, Radovancevic B, Connelly JH, Koerner MM, Entman ME, Frazier OH, Noon GP, Torre-Amione G
Regression of fibrosis and hypertrophy in failing myocardium following mechanical circulatory support.
J Heart Lung Transplant. 2001 Apr;20(4):457-64.
Abstract

Hahalis G, Manolis AS, Gerasimidou I, Alexopoulos D, Sitafidis G, Kourakli A, Korfer R, Koerner MM, Vagenakis AG, Zoumbos NC
Right ventricular diastolic function in beta-thalassemia major: echocardiographic and clinical correlates.
Am Heart J. 2001 Mar;141(3):428-34.
Abstract

Koerner MM, Durand JB, Lafuente JA, Noon GP, Torre-Amione G
Cardiac transplantation: the final therapeutic option for the treatment of heart failure.
Curr Opin Cardiol. 2000 May;15(3):178-82.
Abstract

Tenderich G, Koerner MM, Stuettgen B, Mirow N, Arusoglu L, Morshuis M, Bairaktaris A, Minami K, Koerfer R
Pre-existing elevated pulmonary vascular resistance: long-term hemodynamic follow-up and outcome of recipients after orthotopic heart transplantation.
J Cardiovasc Surg (Torino). 2000 Apr;41(2):215-9.
Abstract

Bartling B, Milting H, Schumann H, Darmer D, Arusoglu L, Koerner MM, El-Banayosy A, Koerfer R, Holtz J, Zerkowski HR
Myocardial gene expression of regulators of myocyte apoptosis and myocyte calcium homeostasis during hemodynamic unloading by ventricular assist devices in patients with end-stage heart failure.
Circulation. 1999 Nov 9;100(19 Suppl):II216-23.
Abstract

Koerner MM, Tenderich G, Minami K, Morshuis M, Mirow N, Arusoglu L, Gromzik H, Wlost S, Koerfer R
Extended donor criteria: use of cardiac allografts after carbon monoxide poisoning.
Transplantation. 1997 May 15;63(9):1358-60.
Abstract

Koerner MM, Tenderich G, Minami K, zu Knyphausen E, Mannebach H, Kleesiek K, Meyer H, Koerfer R
Heart transplantation for end-stage heart failure caused by iron overload.
Br J Haematol. 1997 May;97(2):293-6.
Abstract

Koerner MM, Tenderich G, Minami K, Mannebach H, Koertke H, zu Knyphausen E, El-Banayosy A, Baller D, Kleesiek K, Gleichmann U, Meyer H, Koerfer R
Results of heart transplantation in patients with preexisting malignancies.
Am J Cardiol. 1997 Apr 1;79(7):988-91.
Abstract

Wolff C, Diekmann A, Boomgaarden M, Korner MM, Kleesiek K
Viremia and excretion of TT virus in immunosuppressed heart transplant recipients and in immunocompetent individuals.
Transplantation. 2000 Feb 15;69(3):351-6.
Abstract

Korner MM, Tenderich G, Mannebach H, Minami K, Baller D, Wlost S, Gromzik H, Kleesiek K, Petzoldt R, Korfer R
Extended donor criteria: current donors with a history of prolonged insulin-dependent diabetes mellitus.
Transplant Proc. 1997 Dec;29(8):3664-6.


Korner MM, Tenderich G, Baller D, Mannebach H, Minami K, Arusoglu L, Mirow N, Bairaktaris A, Breymann T, Korfer R
Accepting prolonged ischemia times for the donor heart.
Transplant Proc. 1997 Dec;29(8):3662-3.


Korner MM, Hirata N, Tenderich G, Minami K, Mannebach H, Kleesiek K, Korfer R
Tuberculosis in heart transplant recipients.
Chest. 1997 Feb;111(2):365-9.
Abstract

Wolff D, Korner MM, Wolff C, Korfer R, Kleesiek K
Transfusion-related hepatitis G virus infections in heart transplant recipients.
Transplantation. 1996 Dec 15;62(11):1697-8.


Korfer R, el-Banayosy A, Posival H, Minami K, Kizner L, Arusoglu L, Korner MM
Mechanical circulatory support with the Thoratec assist device in patients with postcardiotomy cardiogenic shock.
Ann Thorac Surg. 1996 Jan;61(1):314-6.
Abstract